Comment from The Geneva Foundation, HHS-OPHS-2018-0021, HHS-OPHS-2018-0021-0001, N/A
The Geneva FoundationOtherIndividual
Summary: The commenter is submitting a clinical trial informed consent form for a study on the efficacy of Tipifarnib in patients with head and neck squamous cell carcinoma. The submission does not express a position on the proposed federal action regarding the posting of consent forms.
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study
Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma
(HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to
First Line Systemic Therapies for HNSCC (SEQ-HN)